Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells

Antiviral therapies are urgently needed to treat and limit the development of severe COVID-19 disease. Ivermectin, a broad-spectrum anti-parasitic agent, has been shown to have anti-SARS-CoV-2 activity in Vero cells at a concentration of 5 μM. These limited in vitro results triggered the investigati...

Descripción completa

Detalles Bibliográficos
Autores principales: Dinesh Kumar, Nilima, ter Ellen, Bram M., Bouma, Ellen M., Troost, Berit, van de Pol, Denise P. I., van der Ende-Metselaar, Heidi H., van Gosliga, Djoke, Apperloo, Leonie, Carpaij, Orestes A., van den Berge, Maarten, Nawijn, Martijn C., Stienstra, Ymkje, Rodenhuis-Zybert, Izabela A., Smit, Jolanda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765325/
https://www.ncbi.nlm.nih.gov/pubmed/34633839
http://dx.doi.org/10.1128/AAC.01543-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765325/
https://www.ncbi.nlm.nih.gov/pubmed/34633839
http://dx.doi.org/10.1128/AAC.01543-21

Ejemplares similares